A3P

Connexion

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

This guideline describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) sections 3.2.S.2.2 – 3.2.S.2.6 (ICH M4Q). It addresses aspects of development and manufacture that pertain to drug substance, including the presence of steps designed to reduce impurities.

Lire la suite...

EMA pharmacovigilance system manual Version 1.2

The EMA pharmacovigilance system is described in this manual, which covers the EMA organisational structure, responsibilities, procedures, processes and resources, appropriate resource management, compliance management and record management. This manual does not cover pharmacovigilance aspects related to veterinary medicines.

Lire la suite...

Submission of Quality Metrics Data Guidance for Industry

Quality metrics are used throughout the drugs and biologics ndustry to monitor quality control systems and processes and drive continuous improvement efforts in drug manufacturing. These metrics can also be useful to FDA: to help develop compliance and inspection policies and practices, such as risk-based inspection scheduling of drug manufacturers; to improve the Agency’s ability to predict, and therefore, possibly mitigate, future drug shortages; and to encourage the pharmaceutical industry to implement state-of-the-art, innovative quality management systems for pharmaceutical manufacturing.

Lire la suite...

Quality Metrics Technical Conformance Guide

This Quality Metrics Technical Conformance Guide (Guide) serves as the technical reference for implementation of the draft FDA guidance for industry on Request for Quality Metrics. Since publication of the Pharmaceutical CGMPs for the 21st Century in 2004, CDER has continued to promote its vision of “a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.”

Lire la suite...

Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry

This guidance describes FDA’s current thinking on defining, establishing, and documenting manufacturing activities of the parties involved in contract drug manufacturing subject to current good manufacturing practice (CGMP) requirements. In particular, we describe how parties involved in contract drug manufacturing can use quality agreements to delineate their manufacturing activities to ensure compliance with CGMP.

Lire la suite...

logo a3p-100pxhaut

 fren

S'engager pour partager
Transmettre et progresser ensemble
Promouvoir l'innovation

L’Association A3P est un acteur incontournable de l’industrie pharmaceutique et biotechnologique. 
Créée en 1986, elle contribue au bon développement de la production de médicaments et de matériels propres et stériles, elle anime un réseau de 21 000 professionnels, fabricants et fournisseurs, dans le cadre de Congrès internationaux et de journées techniques.

Elle regroupe aujourd’hui plus de 1700 adhérents qui partagent leurs expériences techniques, scientifiques et réglementaires.

 + d'infos en vidéo ( version gb - drapeauitalie )


  group    Administrateurs A3P
    
& Chargés de missions

letter   Newsletter A3P
NAVIGATEUR A3P est un outil regroupant la majorité des liens vers les textes, guides, documents et sites réglementaires pour les industries pharmaceutiques, biotechnologies et biomédicales.
  • BPF & Guides

  • Sites Pays

  • Sites Réglementaires

  • Domaines Pharma

  • Autres Sites

   Version 1.00                                                                                                               youtube   linkedin